Non-annotated gene. Preliminary data : if you are an author who wish to write a full paper/card on this gene, contribute in submission tool
Other Information
Locus ID:
NCBI: 55252
MIM: 612991
HGNC: 23805
Ensembl: ENSG00000143970
Variants:
dbSNP: 55252
ClinVar: 55252
TCGA: ENSG00000143970
COSMIC: ASXL2
RNA/Proteins
| Gene ID | Transcript ID | Uniprot |
|---|---|---|
| ENSG00000143970 | ENST00000336112 | E7EWD6 |
| ENSG00000143970 | ENST00000404843 | Q76L83 |
| ENSG00000143970 | ENST00000435504 | Q76L83 |
Expression (GTEx)
Pathways
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 33731362 | 2021 | Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase. | 1 |
| 33751773 | 2021 | Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature. | 7 |
| 33812414 | 2021 | [The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia]. | 0 |
| 33731362 | 2021 | Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase. | 1 |
| 33751773 | 2021 | Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature. | 7 |
| 33812414 | 2021 | [The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia]. | 0 |
| 32027264 | 2020 | [Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene]. | 0 |
| 32945427 | 2020 | Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension. | 12 |
| 32027264 | 2020 | [Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene]. | 0 |
| 32945427 | 2020 | Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension. | 12 |
| 30251205 | 2019 | Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. | 15 |
| 31637484 | 2019 | ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia. | 1 |
| 30251205 | 2019 | Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. | 15 |
| 31637484 | 2019 | ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia. | 1 |
| 29284740 | 2018 | Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. | 12 |
Citation
Dessen P
ASXL2 (ASXL transcriptional regulator 2)
Atlas Genet Cytogenet Oncol Haematol. 2012-11-01
Online version: http://atlasgeneticsoncology.org/gene/52971
